Osteoclasts: Malefactors of disease and targets for treatment

Discovery Medicine

Volumn 13, Issue 70, 2012, Pages 201-210

  Edwards, James R ^a   Weivoda, Megan M ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ODANACATIB; OSTEOCALCIN;

ALBERS SCHOENBERG DISEASE; APOPTOSIS; ARTICLE; BONE DENSITY; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; ENERGY METABOLISM; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INSULIN SENSITIVITY; OSSIFICATION; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PAGET BONE DISEASE; PYCNODYSOSTOSIS; SIGNAL TRANSDUCTION; ANIMAL; BONE DISEASE; DRUG EFFECT; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; BONE DISEASES; HUMANS; OSTEOCLASTS;

EID: 84866786694     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Albagha O, Rojas J, Van't Hof R, Dorin J, Ralston S. A mouse model of early onset Paget's disease of bone caused by an insertion mutation affecting the RANK signal peptide. Calcif Tissue Int 80:s34, 2007
2. Albagha O, Visconti M, Alonso N, Langston A, Cundy T, Dargie R, Dunlop M, Fraser W, Hooper M, Isaia G, Nicholson G, del Pino Montes J, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh J, Ralston S. Genome-wide association study identifies variants at CSF1, OPTN, and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 42(6):520-524, 2010
3. Albagha OM, Pettersson U, Stewart A, McGuigan FE, MacDonald HM, Reid DM, Ralston SH. Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet 42(3):240-246, 2005
4. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson D, Suda T. Commitment and differentiation of osteoclast precursor cells by sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190(12):1741-1754, 1999
5. Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 12(6):915-921, 1997
6. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y, Takeda E. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 16(7):1256-1264, 2001
7. Athanasou N. Cellular biology of bone-resorbing cells. J Bone Joint Surg Am 78(7):1096-1112, 1996
8. Athanasou N. The osteoclast-what's new? Skeletal Radiol 40(9):1137-1140, 2011
9. Basle M, Russell W, Goswami K, Rebel A, Giraudon P, Wild F, Filmon R. Paramyxovirus antigens in osteoclasts from Paget's bone tissue detected by monoclonal antibodies. J Gen Virol 66:2103-2110, 1985
10. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19(7):1059-1066, 2004
11. Blair H, Teitelbaum S, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857, 1989
12. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25(5):937-947, 2010
13. Bonewald L, Mundy G. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res 250:261-276, 1990
14. Cavey J, Ralston S, Hocking L, Sheppard P, Ciani B, Searle M, Layfield R. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20(4):619-624, 2005
15. Clarke BL, Khosla S. Modulators of androgen and estrogen receptor activity. Crit Rev Eukaryot Gene Expr 20(4):275-294, 2010
16. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer F, Beaverson K, Aledo A, Whyte M, Yoneyama T, DeVernjoul M, Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10(25):2861-2867, 2001
17. Crockett J, Mellis D, Scott D, Helfrich M. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 22(1):1-20, 2011
18. Cundy T, Hedge M, Naot D, Chong B, King A, Wallace R, Mulley J, Love D, Seidel J, Fawkner M, Banovic T, Callon K, Grey A, Reid I, Middleton-Hardie C, Cornish J. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11(18):2119-2127, 2002
19. Cundy T, Reid IR. Paget's disease of bone. Clin Biochem 45(1-2):43-48, 2012
20. Di Rocco M, Buoncompagni A, Loy A, Dellacqua A. Osteopetrorickets: case report. Eur J Pediatr 159(8):579-581, 2000
21. Edwards J, Mundy G. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7(4):235-243, 2011
22. Edwards J, Zainabadi K, Elefteriou F, Lwin S, Moore M, Guarente L, Mundy G. The Longevity Gene SIRT-1 Independently Controls Both Osteoblast and Osteoclast Function. J Bone Miner Res 23(S1):28, 2008
23. Engelke J, Hale J, Suttie J, Price P. Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochim Biophys Acta 1078:31-34, 1991
24. Everts V, Aronson D, Beertsen W. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 37(1):25-31, 1985
25. Everts V, Beertsen, W, Tigchelaar-Gutter, W. The digestion of phagocytosed collagen is inhibited by the proteinase inhibitors leupeptin and E-64. Coll Relat Res 5(4):316-336, 1985
26. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 105:5266-5270, 2008
27. Ferron M, Wei, J, Yoshizawa, T, Del Fattore, A, DePinho, RA, Teti, A, Ducy, P, Karsenty, G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142(2):296-308, 2010
28. Frattini A, Orchard P, Sobacchi C, Giliani S, Abinun M, Mattsson J, Keeling D, Andersson A, Wallbrandt P, Zecca L, Notarangelo L, Vezzoni P, Villa A. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25(3):343-346, 2000
29. Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb B, Fratzl P, Klaushofer K. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 89(4):1538-1547, 2004
30. Gelb B, Shi G, Chapman H, Desnick R. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273(5279):1236-1238, 1996
31. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 14(2):203-205, 1996
32. Graves A, PK C, Smith C, Mindell J. The Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453(7196):788-792, 2008
33. Hauschka P, Lian J, Cole D, Gundberg C. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047, 1989
34. Helfrich M. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15(12):2315-2329, 2000
35. Helfrich M. Osteoclast diseases. Microsc Res Tech 61(6):514-532, 2003
36. Helfrich M, Hocking L. Genetics and aetiology of Pagetic disorders of bone. Arch Biochem Biophys 473(2):172-182, 2008
37. Hughes A, Ralston S, Marken J, Bell C, MacPherson H, Wallace R, van Hul W, Whyte M, Nakatsuka K, Hovy L, Anderson D. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24:45-48, 2000
38. Ivaska K, Hentunen T, Vaaraniemi J, Ylipahkala H, Pettersson K, Vaananen H. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279:18361-18369, 2004
39. Jin H, van't Hof RJ, Albagha OM, Ralston SH. Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. Hum Mol Genet 18(15):2729-2738, 2009
40. Jones D, Glimcher L, Aliprantis A. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest 121(7):2534-2542, 2011
41. Kanis J. Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz, London, United Kingdom, 1998
42. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 95(1):3-10, 2010a
43. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 95(8):3569-3577, 2010b
44. Kiesel J, Buchwald Z, Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 182(9):5477-5487, 2009
45. Kornak U, Kasper, D, Bosl, MR, Kaiser, E, Schweizer, M, Schulz, A, Friedrich, W, Delling, G, Jentsch, TJ. Loss of ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104(2):205-215, 2001
46. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch T, Kubisch C. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9(13):2059-2063, 2000
47. Kostenuik P, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7(8):613-635, 2001
48. Laitala T, Vaananen K. Proton channel part of vacuolar H(+)-ATPase and carbonic anhydrase II expression is stimulated in resorbing osteoclasts. J Bone Miner Res 8(1):119-126, 1993
49. Laitala T, Vaananen, HK. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest 93(6):2311-2318, 1994
50. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20(3):289-294, 1997
51. Layfield R, Ciani B, Ralston S, Hocking L, Sheppard P, Searle M, Cavey J. Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. Biochem Soc Trans 32:728-730, 2004
52. Lee N, Sowa H, Hinoi E, Ferron M, Ahn J, Confavreux C, Dacquin R, Mee P, McKee M, Jung D, Zhang Z, Kim J, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 130(3):456-469, 2007
53. Lee S, Rho J, Jeong D, Sul J, Kim T, Kim N, Kang J, Miyamoto T, Suda T, Lee S, Pignolo R, Koczon-Jaremko B, Lorenzo J, Choi Y. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12(12):1403-1409, 2006
54. Li D, Gromov K, Proulx S, Xie C, Li J, Crane D, Soballe K, O'Keefe R, Awad H, Xing L, Schwarz E. Effects of antiresorptive agents on osteomyelitis. Ann NY Acad Sci 177(1):280-290, 2010a
55. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116(2):210-217, 2010b
56. Li J, Sarosi I, Yan X, Morony S, Capparelli C, Tan H, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan S, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97(4):1566-1571, 2000
57. Lorenzo J. Do osteoclasts have dual roles: bone resorption and antigen presentation? IBMS BoneKey 8(1):37-40, 2011
58. Loria-Cortes R, Quesada-Calvo E, Cordero-Chaverri C. Osteopetrosis in children: a report of 26 cases. J Pediatr 91(1):43-47, 1977
59. Lum L, Wong B, Josien R, Becherer J, Erdjument-Bromage H, SchlondorffJ, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274(19):13613-13618, 1999
60. Mazo I, Honczarenko M, Leung H, Cavanagh L, Bonasio R, Weninger W, Engelke K, Xia L, McEver R, Koni P, Silberstein L, von Andrian U. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22(2):259-270, 2005
61. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821-831, 2006
62. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10(4):330-336, 1999
63. Mills B, Singer F, Weiner L, Suffin S, Stabile E, Holst P. Evidence for both respiratory synctial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop 183:303-311, 1984
64. Mohan S, Baylink D. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res 45:59-62, 1996
65. Nakatsuka K, Nishizawa Y, Ralston S. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 18(8):1381-1385, 2003
66. Naot D, Bava U, Matthews B, Callon K, Gamble G, Black M, Song S, Pitto R, Cundy T, Cornish J, Reid I. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 22(2):298-309, 2007
67. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 78(2):355-360, 1986
68. Okumura S, Mizoguchi T, Sato N, Yamaki M, Kobayashi Y, Yamauchi H, Ozawa H, Udagawa N, Takahashi N. Coordination of microtubules and the actin cytoskeleton is important in osteoclast function, but calcitonin disrupts sealing zones without affecting microtubule networks. Bone 39(4):684-693, 2006
69. Ooi C, Walsh C, Gallagher J, Fraser W. Absence of measles virus and canine distemper virus transcripts in long-term bone marrow cultures from patients with Paget's disease of bone. Bone 27:417-421, 2000
70. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115(12):3318-3325, 2005
71. Ralston S. Juvenile Paget's disease, familial expansile osteolysis, and other genetic osteolytic disorders. Best Pract Res Clin Rhematol 22(1):101-111, 2008a
72. Ralston S, Helfrich M. Are paramyxoviruses involved in Paget's disease? A negative view. Bone 24:17S-18S, 1999
73. Ralston S, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 372(9633):155-163, 2008b
74. Ralston SH. Genetics of osteoporosis. Ann N Y Acad Sci 1192:181-189, 2010
75. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB, Hofman A, Pols HA, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371(9623):1505-1512, 2008
76. Riches PL, McRorie E, Fraser WD, Determann C, van't Hof R, Ralston SH. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 361(15):1459-1465, 2009
77. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49(1):34-41, 2011
78. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 122(5):409-414, 2009
79. Ross F, Teitelbaum S. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 208:88-105, 2005
80. Roth D, Venta P, Tashian R, Sly W. Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A 89(5):1804-1808, 1992
81. Russell RG. Bisphosphonates: the first 40 years. Bone 49(1):2-19, 2011
82. Ryu J, Kim H, Chang E, Huang H, Banno Y, Kim H. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoblast-osteoclast coupling. EMBO J 25:5840-5851, 2006
83. Schafer A, Sellmeyer D, Schwartz A, Rosen C, VittinghoffE, Palermo L, Bilezikian J, Shoback D, Black D. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 96(12):E1982-E1989, 2011
84. Selby P, Davie M, Ralston S, Stone M. Guidelines on the management of Paget's disease of bone. Bone 31(3):366-373, 2002
85. Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R, Nguyen H, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309-319, 1997
86. Sly W, Hewett-Emmett D, Whyte M, Yu Y, Tashian R. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 80(9):2752-2756, 1983
87. Smink JJ, Leutz A. Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases. J Mol Med (Berl) 88(3):227-233, 2010
88. Sobacchi C, Frattini A, Guerrini M, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39(8):960-962, 2007
89. Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson GN. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 89(1):344-351, 2004
90. Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86(2):175-182, 2009
91. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358(22):2355-2365, 2008
92. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradottir S, Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. New sequence variants associated with bone mineral density. Nat Genet 41(1):15-17, 2009
93. Susani L, Pangrazio A, Sobacchi C, Taranta A, Mortier G, Savarirayan R, Villa A, Orchard P, Vezzoni P, Albertini A, Frattini A. TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 24(3):225-235, 2004
94. Takata S, Yasui N, Nakatsuka K, Ralston S. Evolution of understanding of genetics of Paget's disease of bone and related diseases. J Bone Miner Metab 22(6):519-523, 2004
95. Taranta A, Brama M, Teti A, Deluca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30(2):368-376, 2002
96. Teitelbaum S. Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427-435, 2007
97. Tolar J, Teitelbaum S, Orchard P. Osteopetrosis. N Engl J Med 351(27):2839-2849, 2004
98. Vaananen H, Zhao H, Mulari M, Halleen J. The cell biology of osteoclast function. J Cell Sci 113:377-381, 2000
99. Villa A, Guerrini M, Cassani B, Pangrazio A, Sobacchi C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tiss Int 84:1-12, 2009
100. Whyte M. Carbonic anhydrase II deficiency. Clin Orthop Relat Res Sep(294):52-63, 1993.
101. Whyte M, Hughes, AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17(1):26-29, 2002.
102. Whyte M, Obrecht S, Finnegan P, Jones J, Podgornik M, McAlister W, Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347(3):175-184, 2002.
103. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4(2):111-121, 2006.